25 results on '"Dahlof, Bjorn"'
Search Results
2. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
3. CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDING
4. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (the PRESERVE study)
5. STATIN USE AND RISK OF NEW DIABETES MELLITUS IN HYPERTENSivE PATIENTS: THE LIFE STUDY
6. LOW IN-TREATMENT HDL CHOLESTEROL LEVELS STRONGLY PREDICT THE DEVELOPMENT OF NEW STROKE: THE LIFE STUDY
7. RELATIONSHIPS BETWEEN SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HIGH RISK HYPERTENSION: AN ANALYSIS OF THE ACCOMPLISH TRIAL
8. INFLUENCE OF DIABETES ON LEFT VENTRICULAR MASS REGRESSION WITH ALISKIREN, LOSARTAN OR BOTH
9. 882-1 Anglo-scandinavian cardiac outcomes trial — lipid-lowering arm (ASCOT-LLA): Results in the subgroup of patients with diabetes
10. 1085-170 Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: A LIFE substudy
11. 812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study
12. 1009-166 Pulse pressure as cardiovascular risk marker during losartan or atenolol based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial)
13. Ethnicity, left ventricular hypertrophy regression and cardiovascular events in the life echocardiography substudy
14. Association of left bundle branch block with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: the life study
15. Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the life study
16. Relation of serum uric acid to cardiovascular endpoints in hypertension: the life study
17. Association of left ventricular hypertrophy regression and heart rate reduction with determinants of myocardial oxygen consumption and cardiovascular events: The LIFE study
18. Hypertensive patients with diabetes have less regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study
19. Losartan reduces hospitalization for heart failure in patients with diabetes and no prior history of heart failure
20. Regression of echocardiographic left ventricular hypertrophy in relation to resolution versus persistence of electrocardiographic strain after one year of antihypertensive therapy: the LIFE study
21. Left ventricular mass change during treatment and outcome in hypertensive patients with left ventricular hypertrophy: the LIFE trial
22. Differences in heart rate variabilty in African-American vs Caucasian hypertensives with left ventricualr hypertrophy: the LIFE study
23. Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): blood pressure changes at 2.5 years of follow-up
24. Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial
25. Age-related changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The preserve study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.